Concomitant use of sorafenib with ombitasvir/paritaprevir/ritonavir and dasabuvir: Effectiveness and safety in clinical practice | Zendy

RevueltaHerrero J. L. | Zendy; GiménezManzorro A. | Zendy; MatillaPeña A. | Zendy; HerranzAlonso A. | Zendy; SanjurjoSáez M. | Zendy

Premium

Concomitant use of sorafenib with ombitasvir/paritaprevir/ritonavir and dasabuvir: Effectiveness and safety in clinical practice

Author(s) -

RevueltaHerrero J. L.,

GiménezManzorro A.,

MatillaPeña A.,

HerranzAlonso A.,

SanjurjoSáez M.

Publication year - 2018

Publication title -

journal of clinical pharmacy and therapeutics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.622

H-Index - 73

eISSN - 1365-2710

pISSN - 0269-4727

DOI - 10.1111/jcpt.12727

Subject(s) - ombitasvir , dasabuvir , ritonavir , paritaprevir , sorafenib , concomitant , medicine , adverse effect , hepatocellular carcinoma , gastroenterology , hepatitis c virus , virology , viral load , ribavirin , virus , antiretroviral therapy

Summary What is known and objective No studies have evaluated the use of sorafenib with the direct‐acting antiviral ombitasvir/paritaprevir/ritonavir and dasabuvir ( OBV / PTV /r+ DSV ). Case summary Three hepatitis C virus genotype 1b‐infected patients with well‐preserved liver function were included in this prospective case series. The patients were taking sorafenib for advanced hepatocellular carcinoma and received OBV / PTV /r+ DSV for 12 weeks. One patient discontinued sorafenib while concomitant treatment due to grade 2 fatigue and muscular pain. The other two patients reported only grade 1 adverse effects. Sustained virologic response at 24 weeks was achieved, and no tumour recurrences were found. What is new and conclusion The concurrent use of OBV / PTV /r+ DSV with sorafenib was considered safe and effective.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research